RECOGNITION AND ASSESSMENT

Symptoms and signs

  • Severe diarrhoea, tenesmus
  • Abdominal pain
  • Anorexia, weight loss
  • Malaise
  • Variable amount of blood in stool
  • Dehydration
  • Tachycardia
  • Fever
  • Anaemia

Life-threatening features

  • Severe sepsis/septic shock
  • Toxic dilatation of colon
  • Perforation of colon
  • Profound electrolyte disturbance
  • Massive haemorrhage
  • Obvious weight loss
  • Secondary multi-organ failure

Investigations

  • FBC
  • U&E
  • LFT
  • CRP
  • Blood glucose
  • Abdominal X-ray
  • Erect chest X-ray – look for gas under diaphragm
  • Stool culture (Salmonella, Shigella, Campylobacter), Clostridium difficile toxin
  • Crossmatch: group and save
  • Arterial blood gases

Differential diagnosis

  • Bacterial and amoebic colitis (history of travel)
  • Pseudomembranous colitis (history of antimicrobial use)
  • Diverticular disease
  • Ischaemic colitis
  • Bowel cancer
  • Abdominal lymphoma
  • Radiation colitis
  • Ileocaecal TB

IMMEDIATE TREATMENT

Logistics

  • If needed, contact on-call consultant gastroenterologist
  • In patients with life-threatening features inform duty surgical team
  • Barrier nurse
    • inflammatory bowel disease can at first be indistinguishable from infective diarrhoea
  • Admit to GI ward

Drugs and fluid

  • Establish IV access and correct dehydration/electrolyte disturbance
  • If Hb <80 g/L, give blood transfusion
    • 4 units plus an extra unit for each g/L below 80
  • Hydrocortisone 200 mg 8-hrly by slow IV injection over 1 min
  • Ensure all patients receive prophylactic dalteparin
  • DO NOT GIVE anti-diarrhoeal drugs in acute phase
    • increase the risk of toxic dilatation
  • DO NOT PERFORM colonoscopy in acute phase
    • high risk of perforation of the colon

SUBSEQUENT MANAGEMENT

  • Once infective element has been excluded, relax barrier nursing restrictions
  • Ensure patient discussed with consultant gastroenterologist

If improving

  • Substitute prednisolone (not enteric coated) 40 mg oral daily in place of hydrocortisone
    • taper dose by 5mg every week
    • co-prescribe calcium and vitamin D whilst on prednisolone
  • Start restricted oral feeding. Seek dietetic opinion
  • Give mesalazine (Octasa® MR) 800 mg oral 8-hrly
  • For distal disease, consider hydrocortisone foam enema 10% 12–24 hrly for 2–3 weeks
  • If extent and severity of inflammation not apparent from supine plain abdominal X-ray
    • consult with consultant gastroenterologist to:
    • plan colonoscopy in convalescent phase

If not improving

  • If no improvement after 48 hr, consider escalation therapy with:
    • either IV ciclosporin (unlicensed) or infliximab
    • only after discussion with a consultant gastroenterologist
  • If still no improvement by day 5, consider surgery

MONITORING TREATMENT

2-hrly

  • Temperature
  • Pulse
  • BP
  • Respiration

Twice daily

  • Abdominal examination
    • look for local peritonism and check bowel sounds
  • Measure abdominal girth

Daily

  • FBC, U&E, stool culture
  • abdominal X-ray
    • look for free abdominal gas or colonic dilatation >6 cm
  • Count stools and inspect for blood

Alternate days

  • Erect chest X-ray: look for gas under diaphragm

DISCHARGE AND FOLLOW-UP

Plan home treatment regimen

  • Prednisolone (not enteric coated)
    • taper daily dosage by 5 mg each week to zero or previous maintenance dosage
    • co-prescribe calcium and vitamin D whilst on prednisolone
  • If distal disease, Hydrocortisone foam enema 10% 12–24 hrly
  • Mesalazine (Octasa® MR), usually 800 mg 8-hrly but higher doses (up to 4.8 g/day) can be used if needed
  • Nutritional support, as advised by dietitian

Follow-up

  • If outpatient colonoscopy not already performed, arrange in consultation with consultant gastroenterologist
  • Arrange follow-up in gastrointestinal outpatient clinic after 4 weeks
  • Give patient information literature and encourage membership of Crohn’s and Colitis UK
  • Inform IBD Nurses of admission especially if new diagnosis

© 2022 The Bedside Clinical Guidelines Partnership.

Created by University Hospital North Midlands and Keele University School of Computing and Mathematics.

Research and development team: James Mitchell, Ed de Quincey, Charles Pantin, Naveed Mustfa